Vitruvias Therapeutics recalls
2 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Vitruvias Therapeutics and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-09-23FDA-DrugClass IVitruvias Therapeutics thyroid tablets recalled for superpotency
Vitruvias Therapeutics is recalling Thyroid Tablets, USP 1/2 Grain (30 mg) because the tablets are superpotent—meaning they contain higher-than-intended levels of active ingredients. This lot was distributed nationwide. The affected lot number is 504950, expiring 09/30/2026.
- 2026-08-21FDA-PRVitruvias Thyroid Tablets recalled for super potency risk
Vitruvias Therapeutics is recalling one lot (504950) of Thyroid Tablets, USP 30 mg because testing found the tablets may contain higher-than-intended amounts of thyroid hormone. Taking overly potent thyroid medication can cause an overactive thyroid, leading to weight loss, rapid heartbeat, chest pain, and other serious symptoms, especially in elderly people, pregnant women, and infants.
Get the week's recalls, including Vitruvias Therapeutics
Free weekly digest — every federal recall affecting your household, Vitruvias Therapeutics included when it comes up. Track Vitruvias Therapeutics specifically with Always-on.